VRAX
Virax Biolabs Group·NASDAQ
--
--(--)
--
--(--)
3.59 / 10
Netural
Fund flow score of 7.18/10 indicates robust capital inflow, yet all size-based trends (block, small, medium, large, extra-large) are negative, suggesting potential short-term volatility. Analyst coverage is minimal (one Strong Buy; historical win-rate 0.0%), and market-weighted expectations are pessimistic, aligning with the cautious stance.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for VRAX?
- VRAX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.59/10 (Netural).
